Crispr Stock Tumbles On FDA Clinical Hold, But European Study Remains On Track – Seeking Alpha
Seeking Alpha |
Crispr Stock Tumbles On FDA Clinical Hold, But European Study Remains On Track
Seeking Alpha Crispr Therapeutics received a clinical hold from the FDA for an IND on CTX-001 in treating patients with sickle cell disease. An FDA clinical hold on an IND is rare, but it is highly likely that the FDA is just being cautious with a newer form of … |
